For the Inventor, By the Inventor

Enter assignee name

San Francisco, CA, United States of America

Nurix Therapeutics, Inc.

USPTO Granted Patents = 22

EPO Patents = 4

Forward Citations = 37

Loading Chart...

Loading Chart...

40 inventors (with patents filed for the assignee):

Arthur T Sands (17 out of 17 patents)

Dahlia Weiss (11 out of 11 patents)

Jennifa Gosling (10 out of 14 patents)

4. Frederick Cohen (9 out of 29 patents)

5. Hunter Paul Shunatona (9 out of 26 patents)

6. Neil F Bence (8 out of 8 patents)

7. Thomas Cummins (8 out of 8 patents)

8. Christoph Wolfgang Zapf (8 out of 25 patents)

9. Mario G Cardozo (8 out of 24 patents)

10. Chenbo Wang (7 out of 7 patents)

11. Hiroko Tanaka (7 out of 7 patents)

12. Jeffrey Wu (5 out of 6 patents)

13. Daniel W Robbins (4 out of 4 patents)

14. Daisuke Kato (4 out of 4 patents)

15. Jeffrey Thomas Mihalic (4 out of 34 patents)

22 patents: Sort by Forward Citations

1. 12653809 - UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION (2026-06-16),

2. 12600732 - Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway (2026-04-14),

3. 12594263 - CBL inhibitors and compositions for expansion of immune cells (2026-04-07),

4. 12583862 - Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway (2026-03-24),

5. 12582722 - Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway (2026-03-24),

6. 12570662 - Substituted pyrrolo[1,2-b]pyridazines as bifunctional degraders of interleukin-1 receptor-associated kinases (2026-03-10),

7. 12528814 - Bifunctional degraders of interleukin-1 receptor-associated kinases and therapeutic use thereof (2026-01-20),

8. 12485144 - 3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE THEREOF (2025-12-02),

9. 12377106 - Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading BTK (2025-08-05),

10. 12234230 - Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof (2025-02-25),

11. 12121540 - CBL inhibitors and compositions for use in adoptive cell therapy (2024-10-22),

12. 12091426 - Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof (2024-09-17),

13. 12049471 - Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof (2024-07-30),

14. 12016860 - Combination therapies with Cbl-b inhibitor compounds (2024-06-25),

15. 11951133 - 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof (2024-04-09),

Company Overview

Nurix Therapeutics, Inc. is a biotechnology company based in San Francisco, California, focused on the discovery and development of innovative therapies for cancer and other serious diseases. The company specializes in harnessing the power of targeted protein modulation to create novel treatments that can effectively address unmet medical needs. With a strong emphasis on research and development, Nurix aims to advance its proprietary technology platforms to transform the landscape of therapeutic options available to patients.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

22 Patents

#208 in San Francisco, CA

#3,586 in California

#15,037 in US

#28,782 in the World

San Francisco, CA, United States of America

Nurix Therapeutics, Inc.

Forward Citations = 37

40 inventors:

Arthur T Sands (17 out of 17 patents)

Dahlia Weiss (11 out of 11 patents)

Jennifa Gosling (10 out of 14 patents)

4. Frederick Cohen (9 out of 29 patents)

5. Hunter Paul Shunatona (9 out of 26 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Nurix Therapeutics, Inc.. Retrieved from https://idiyas.com/company/nurix-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…